ClinicalTrials.gg
Not yet recruitingNCT05802342Updated Apr 6, 2023

A Multicenter, Randomized, Double-blind Phase II Trial to Evaluate GM1 Prevention of Peripheral Neuropathy in Patients With Breast Cancer

A Phase 2/3 interventional study of Monosialotetrahexose ganglioside sodium injection in To Evaluate the Effectiveness of GM1 in the Prevention of Albumin-paclitaxel Therapy Induced Peripheral Neuropathy in Breast Cancer Patients, sponsored by Qilu Pharmaceutical Co., Ltd.. Not yet recruiting. Open to female participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2023-04-06.

Sponsored by Qilu Pharmaceutical Co., Ltd. · Phase 2/3, Interventional, and Prevention

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as not yet recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
150
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Breast Neoplasms by Qilu Pharmaceutical Co., Ltd. — 6 open to participants now, 6 under way, 2 of them phase 3. Breast Neoplasms · Qilu Pharmaceutical Co., Ltd..

Planned enrollment
6th of 10
150 · median 225
Started
2023
the only one that year
Phase 2/3
Only one
of the 10
Registered
5th of 10
by date

Among the 10 studies in Breast Neoplasms by Qilu Pharmaceutical Co., Ltd., this one is the 6th largest by planned enrollment, is the only one that started in 2023, is the only one in phase 2/3, and was the 5th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

6 of the 10 studies in Breast Neoplasms by Qilu Pharmaceutical Co., Ltd. are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 6 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 75 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Breast Neoplasms by Qilu Pharmaceutical Co., Ltd., or all of them as a file.
02

Study summary

This randomized, double-blind, multicenter, placebo-controlled Phase II trial was designed to investigate the efficacy and safety of GM1 in the prevention of peripheral neuropathy caused by albumin-bound paclitaxel regimen in breast cancer patients.This study was randomly divided into 3 groups at 1:1:1 with 50 subjects in each group Subjects received study treatment until the end of treatment for a total of 4/6 cycles. The treatment period was GM1/ placebo combined with albumin-bound paclitaxel therapy. GM1 / placebo was administered 1 day before administration (D0), on the day of administration (D1) and on the day after administration (D2), and albumin-bound paclitaxel was administered starting on day D1, with a total of 4/6 cycles.

03

Conditions studied

  • To Evaluate the Effectiveness of GM1 in the Prevention of Albumin-paclitaxel Therapy Induced Peripheral Neuropathy in Breast Cancer Patients

Browse trials for

04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Fully understand the content of the experiment and voluntarily sign the ;
  2. Age from 18 to 75 years old (including both ends);
  3. Breast cancer patients who provide definitive histological and/or cytological diagnosis of breast cancer and are proposing /neoadjuvant therapy with the albumin-paclitaxel regimen;
  4. score 0\~1;
  5. The organ function level must meet the requirements
  6. Subjects (both male and female) agreed to use effective from the time of signing the informed consent to 30 days after the last use of the study drug. Female subjects of childbearing age cannot be pregnant or lactating.
  7. Patients can accurately record or express the occurrence and severity of neurotoxicity in questionnaires;
  8. After enrollment, patients should not receive other treatments or care that might prevent or treat neurotoxic adverse events

Exclusion criteria

Exclusion Criteria:

  1. Presence of grade 1 peripheral neurotoxicity (≥1) or symptoms of peripheral neuropathy (FACT/GOG-Ntx≥1)
  2. There are risk factors for peripheral neuropathy (except peripheral neuropathy caused by chemotherapy),Including but not limited to: diabetic peripheral neuropathy; Peripheral vascular disease; Folic acid, B12 vitamin deficiency; Postoperative neuropathy; Post-traumatic neuropathy; Peripheral neuroinflammatory lesions; Peripheral neuropathy caused by tumor compression and infiltration; Other researchers believe that can cause limb pain, numbness, paresthesia, dysfunction of the skin, muscle, vascular diseases;
  3. Cardiovascular and cerebrovascular diseases, including but not limited to: Myocardial infarction (within 6 months before signing the ), unstable angina, high risk of uncontrollable arrhythmia, coronary artery bypass grafting, cerebrovascular accident (within 6 months before signing the informed consent), congestive heart failure (cardiac function grade III-Ⅳ), pulmonary embolism, deep vein thrombosis, and other cardiovascular and cerebrovascular systems deemed unsuitable for inclusion by the investigator General disease;
  4. Uncontrolled hypertension (systolic blood pressure ≥160mmHg and/or diastolic blood pressure ≥100mmHg) after optimal treatment with antihypertensive drugs; Patients with blood pressure deemed unsuitable for clinical trials by the investigator;
  5. Diabetic patients with ≥9.0%;
  6. Active bacterial, fungal, or viral infections that require systematic treatment within one week prior to initial administration; Infectious diarrhea occurred within 4 weeks prior to initial administration;
  7. History of inherited abnormal glucose and lipid metabolism (ganglioside accumulation disease, such as familial amaurosis, retinal degeneration) or disease;
  8. (HIV) infection or known acquired immunodeficiency syndrome (AIDS); Syphilis antibody positive;
  9. Active (HBsAg positive with HBV-DNA > 500 IU/ml or lower limit of Center detection [only when lower limit of Center detection is higher than 500 IU/ml]), active (patients with HCV antibody positive but HCV-RNA \< lower limit of Center detection are admitted);
  10. Known allergy to ganglioside drugs or any component of such products; Or to treat an allergy to a drug or any excipient component of such product;
  11. Patients who, in the judgment of the investigator, may increase the risk associated with the study, may interfere with the interpretation of the study results, or may be deemed unsuitable for inclusion by the investigator and/or sponsor.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
150 participants (estimated)

Study arms

  • Experimental
    A

    GM1 (100 mg) + albumin paclitaxel

    Drug: Monosialotetrahexose ganglioside sodium injection

  • Experimental
    B

    GM1 (400 mg) + albumin paclitaxel

    Drug: Monosialotetrahexose ganglioside sodium injection

  • Placebo comparator
    C

    placebo + albumin paclitaxel

    Drug: Monosialotetrahexose ganglioside sodium injection

Interventions

  • DrugMonosialotetrahexose ganglioside sodium injection

    The treatment period was GM1/ placebo with albumin-paclitaxel from cycle 1 to cycle 4/6. The treatment period was GM1/ placebo with albumin-paclitaxel. GM1/ placebo was administered every 2 weeks /3 weeks. GM1 / placebo was administered 1 day before administration (D0), on the day of administration (D1) and on the day after administration (D2), and albumin-paclitaxel-based chemotherapy was administered from day 1, with a total of 4/6 cycles of administration. GM1/ placebo was administered every 2 weeks /3 weeks. GM1 / placebo was administered 1 day before administration (D0), on the day of administration (D1) and on the day after administration (D2), and albumin-paclitaxel-based chemotherapy was administered from day 1, with a total of 4/6 cycles of administration.

06

What researchers measure

Primary outcomes

  1. Grade ≥2 neurotoxicity (CTCAE)

    Time frame: C4D3

  2. The difference between the FACT/GOG-Ntx score and the baseline score

    Time frame: C4D3

Secondary outcomes

  1. The incidence of peripheral neurotoxicity during cycles 1 to 6 and follow-up

    Time frame: 12 month

  2. Change in FACT/GOG-Ntx scores from baseline during 1-6 cycles and follow-up

    Time frame: 12 month

  3. Change in CIPN20 score from baseline after 1-6 cycles and follow-up

    Time frame: 12 month

  4. incidence of adverse events

    Time frame: 12 month

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2023; primary completion for Dec 2024, 20 months later.

Of 56 phase 2/3 interventional studies under Breast Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 32 and three quarters within 88. This study's planned 20 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 27, 2023
First posted
Apr 6, 2023
StartEst.
Apr 20, 2023
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2025
Last update
Apr 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05802342
Responsible party
Sponsor
First posted
Apr 6, 2023
Start date
Apr 20, 2023 (estimated)
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Apr 6, 2023

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion